Moreover, ERK inhibition was also observed when lapatinib resistant breast cancer cells were treated with Roneparstat [18], consistent with our previous finding that Roneparstat blocks heparanase-induced ERK signaling [12]. Here, HPSE is linked to breast carcinoma.